Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01502943
Other study ID # 2009ZX09502-029
Secondary ID
Status Completed
Phase Phase 4
First received December 15, 2011
Last updated December 30, 2011
Start date May 2011
Est. completion date December 2011

Study information

Verified date December 2011
Source Liaoning University of Traditional Chinese Medicine
Contact n/a
Is FDA regulated No
Health authority China: State Administration of Traditional Chinese Medicine of the People's Republic of China
Study type Interventional

Clinical Trial Summary

The purpose of the trial is to take stable angina pectoris of coronary heart disease (CHD) as examples to build a standard evaluation system for efficacy of traditional Chinese medicine (TCM).

1. Studies of evaluating reliability, validity and reactivates of Patients Report Outcomes of CHD and self-administrated scale of Stable Angina Pectoris

2. research on all indicators of CHD, and analyze their characteristics, target and function

3. theory of Invigorating Spleen to Remove Phlegm or replenish Qi, and activating blood and dissolving stasis as an example for clinical efficacy evaluation.


Description:

Clinical efficacy is the basis of traditional Chinese medicine development, and scientific evaluation of TCM clinical efficacy and its effectiveness is the way to push TCM modernized and international. TCM theories of Overall concept and Differentiation for life science and diseases are hard to be generally accepted. Besides, no unified and standard methods fit to evaluate the TCM clinical efficacy. Thus, there is a need to do a deeper research of methodology, evaluative index, and evaluative criteria in order to guide the evaluation of TCM clinical efficacy.

Based on the situation above, the study aims to choose the best and characteristic evaluative index of clinical efficacy, compare the demand among practitioners, patients and care givers. After data collected, a new cluster of index among Biochemical, patients report outcomes, endpoint indicators, and TCM soft indicators could be constituted and analyzed to use in respective way according to their characteristics, target and function.


Recruitment information / eligibility

Status Completed
Enrollment 480
Est. completion date December 2011
Est. primary completion date December 2011
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 45 Years to 75 Years
Eligibility Inclusion criterion:

- The diagnosis standard according with stable angina coronary heart disease

- The participants with any one of the below six standards are included:

- history of myocardial infarction previously

- PCI postoperative patients

- CT showing more than 50% coronary stenosis

- Coronary angiography showing more than 50% coronary stenosis

- positive results of the electrocardiogram

- ischemia changes in the electrocardiogram recently

- The Patients with disease history more than three months, attacked in the recent one month

- Standard according to the phlegm and blood stasis syndrome or Qi deficiency and blood stasis syndrome of the traditional Chinese medicine

- Male: 45 years old < 75 years old

- Female: 50 years old < 75 years old

- Participants signed the agreement paper voluntarily.

Exclusion criterion:

- Participants with Acute coronary syndrome (ST segment elevation myocardial infarction, non ST segment elevation myocardial infarction, unstable angina), asymptomatic myocardial ischemia,ischemic cardiomyopathy,the myocardial infarction happening in the 3 months before the test

- Participants with rheumatism heart disease, hyper thyroid heart disease, hypertensive heart disease, myocarditis, cardiomyopathy

- Participants with Cervical disease, gallbladder cardiac syndrome, stomach and esophageal reflux, aortic dissection

- Participants with acute cerebral infarction and cerebral hemorrhage

- Participants with severe heart failure, lung function, liver function (AST, ALT 1.5 times normal standard), kidney function (BUN, Cr more than the normal standard), hematopoietic system and endocrine systems and serious primary disease, malignant tumor, gastrointestinal bleeding, gastric ulcer and are prone to bleed

- the Participants can not complete the whole test

- The serious high blood pressure and hard to control (SBP >= 180 mmHg or DBP >=110 mmHg)

- Participants of acute or chronic cardiac dysfunction with heart function III-IV

- Participants has been included in other clinical studies in one month;

- Participants with glaucoma

- Participants with Pregnancy Or Lactation ,Allergy

- Participants with mental disorder, or nervous disease, or illiteracy, or bad compliance for questionnaire

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)


Intervention

Drug:
Louxiangdan Tongxin granules
TCM treatment: Decoction: Louxiangdan Tongxin granules Herbs:Danshen 10g?Chenxiang 1g?Gualou10g?Xiebai 10g?Banxia6g?Chuanxiong 6g ?Dangshen 10g?Zhiqiao 6g?Taoren 10g?Guizhi 6g Therapeutic Principle:Invigorating Spleen to Remove Phlegm and activating blood and dissolving stasis, at least 6 kinds of TCM herbs can be chosen and their dosages be adjusted according to Syndrome Differentiation. Usage:Once 100ml, twice per day after breakfast and supper.
TCM granules placebo
Chinese medicine granules placebo: once 100ml, twice per day after breakfast and supper.
Chixiangshen Tongxin granules
TCM treatment: Decoction: Chixiangshen Tongxin granules Herbs: Chishao 10g, Chenxiang 1g, Danggui 10g, Jupi 10g, Yanhusuo 6g, Chuanxiong 6g, Dangshen 10g, Huangqi 6g, Taoren 10g, Honghua 10g Therapeutic Principle:Invigorating Spleen to Replenish Qi and activating blood and dissolving stasis, at least 6 kinds of TCM herbs can be chosen and their dosages be adjusted according to Syndrome Differentiation. Usage:Once 100ml, twice per day after breakfast and supper.
TCM granule placebo plus western basis treatment
Chinese medicine granules placebo: once 100ml, twice per day after breakfast and supper.
Western basis treatment
Aspirin: 100mg pd. P.O.( patients who have Aspirin resistance or Allergy can replaced with Piece clopidogrel 75mg pd. P.O.) Atorvastatin calcium (Lipitor): 10mg pd. P.O.( patients who have Atorvastatin calcium resistance or Allergy can replaced with Additive amount of pravastatin equal to 10mg Lipitor) Nitroglycerin: sublingual necessary.

Locations

Country Name City State
China Affiliated hospital of Changchun university of TCM Changchun Jilin
China Jilin integrative Chinese and western medicine hospital Changchun Jilin
China Dalian integrative of Chinese and Western medicine hospital Dalian Liaoning
China Dandong TCM hospital Dandong Liaoning
China Fuxin TCM hospital Fuxin Liaoning
China Affiliated hospital of Liaoning university of TCM Shenyang Liaoning
China Affiliated hospital of Liaoning university of TCM 2 Shenyang Liaoning
China Shengjing Hospital of China Medical University Shenyang Liaoning
China Affiliated hospital of Tianjin university of TCM Tianjin Tianjin
China Yingkou TCM hospital Yingkou Liaoning

Sponsors (2)

Lead Sponsor Collaborator
Liaoning University of Traditional Chinese Medicine Ministry of Science and Technology of the People´s Republic of China

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary TCM characteristics evaluative index: Traditional Chinese medicine SYndrome Scale (TCMsys) (new developed) Taken at day 1 (baseline) and Change from Baseline in 2nd,4th,8th week No
Primary New developed Quality of life evaluative index: patients report outcomes for SAP Taken at expected day 7 in the screen period, day 1 (baseline) and Change from Baseline in 2nd,4th,8th week No
Primary New developed Quality of life evaluative index: self-administrated scale of SAP Taken at expected day 7 in the screen period, day 1 (baseline) and Change from Baseline in 2nd,4th,8th week No
Secondary Symptoms evaluative index: Measure Your Medical Outcome Profile (MYMOP), Angina incentives, symptom score scale, rate of nitroglycerin, angina classification, heart function classification Taken at day 1 (baseline) and Change from Baseline in 2nd,4th,8th week; and all except MYMOP taken one more at expected day 7 in screen No
Secondary Biochemical index: ECG, ECG exercise test, blood lipids, blood glucose (fasting glucose), Blood, urine, liver function, renal function, coagulation, echocardiography (including heart function), coronary CT (some hospitals choose to do) Taken at expected day 7 in the screening period (baseline) and Change from Baseline in 8th week Yes
Secondary Quality of life evaluative index: Seattle angina questionnaire (SAQ) Taken at day 1 (baseline) , Change from Baseline in 2nd, 4th, 8th, 12th week No
Secondary Quality of life evaluative index: short form-12 (SF-12) Taken at day 1 (baseline), Change from Baseline in 2nd, 4th, 8th, 12th week No
Secondary TCM characteristics evaluative index: Traditional Chinese medicine Syndrome Scale 2 (criteria) Taken at expected day 7 in the Screening period,and Change from Baseline in 2nd,4th,8th week No
Secondary Endpoint index (Cardiovascular events, non-cardiovascular events, death, hospitalization due to coronary heart disease cases) Taken at 2nd, 4th, 8th, 12th, 26th week No
See also
  Status Clinical Trial Phase
Recruiting NCT05196659 - Collaborative Quality Improvement (C-QIP) Study N/A
Completed NCT05088291 - Application of a New X-ray Protective Device in Coronary Interventional Therapy
Completed NCT03076801 - Does Choral Singing Help imprOve Stress in Patients With Ischemic HeaRt Disease? N/A
Completed NCT04584645 - A Digital Flu Intervention for People With Cardiovascular Conditions N/A
Not yet recruiting NCT04995159 - Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System N/A
Recruiting NCT02967718 - Innovation Research of Differentiation and Treatment Methods Based on CHD Phlegm and Blood Stasis Syndrome N/A
Completed NCT02888652 - Study on the Registration of Coronary Heart Disease Patients Undergoing PCI
Completed NCT02163044 - The Hellenic Postprandial Lipemia Study (HPLS)
Terminated NCT02045134 - Supplementation With Polyphenol-Rich Foods and Atrial Fibrillation After a Cardiac Surgery N/A
Active, not recruiting NCT02244853 - Heart Rate and Cardiovascular Diseases Prognosis in People With Stable Coronary Artery Disease N/A
Terminated NCT01906957 - Cognition and Exercise Training N/A
Completed NCT02753829 - Home-based Cardiovascular Rehabilitation, Maintenance Phase, in Subjects With Coronary Artery Disease N/A
Completed NCT02440893 - Understanding the Effect of Metformin on Corus CAD (or ASGES)
Completed NCT01920009 - Impact of Motivational Interviews Within Pharmacy Care Upon Adherence to Cardiovascular Medicines N/A
Completed NCT01826552 - Comparison of the Angiographic Result of the Orsiro Hybrid Stent With Resolute Integrity Stent Phase 4
Recruiting NCT01689688 - Healing Response to Everolimus-eluting Stent Implantation; Serial Assessment With opticaL Coherence Tomography N/A
Completed NCT01779401 - Clopidogrel Response Evaluation and AnTi-Platelet InterVEntion in High Thrombotic Risk PCI Patients N/A
Recruiting NCT01456364 - Intracoronary Stenting and Antithrombotic Regimen: ADjusting Antiplatelet Treatment in PatienTs Based on Platelet Function Testing Phase 4
Recruiting NCT01462799 - COR-PRIM: Problem-based Learning (PBL) After Coronary Heart Disease (CHD) - Long-term Evaluation in Primary Care of Self-care N/A
Completed NCT01486030 - Effect of Exercise Stress Testing on Peripheral Gene Expression Using Corus CAD (or ASGES) Diagnostic Test